We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Glaukos Corp (GKOS) USD0.001

Sell:$44.95 Buy:$44.96 Change: $0.87 (1.90%)
Market closed |  Prices as at close on 22 October 2021 | Switch to live prices |
Change: $0.87 (1.90%)
Market closed |  Prices as at close on 22 October 2021 | Switch to live prices |
Change: $0.87 (1.90%)
Market closed |  Prices as at close on 22 October 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company that is focused on developing therapies for the treatment of glaucoma, corneal disorders, and retinal disease. The Company’s products are designed to treat mild-to-moderate open-angle glaucoma, the iStent, the iStent inject, and the iStent inject W. The Company’s Micro-Invasive Glaucoma Surgery (MIGS) serves as an alternative to the traditional glaucoma treatment paradigm. It offers bio-activated pharmaceutical therapy for the treatment of corneal disorder and keratoconus. It is also developing a pipeline of surgical devices, sustained pharmaceutical therapies, implantable biosensors intended to treat glaucoma progression, corneal disorders such as keratoconus, dry eye, refractive vision correction, retinal diseases such as neovascular age-related macular degeneration, diabetic macular edema and retinal vein occlusion.

Contact details

229 Avenida Fabricante
United States
+1 (949) 3679600

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$2.15 billion
Shares in issue:
46.56 million
Health Care Equipment
New York Stock Exchange
United States
US dollar

Key personnel

  • Thomas Burns
    President, Chief Executive Officer, Director
  • Joseph Gilliam
    Chief Financial Officer, Senior Vice President - Corporate Development
  • Chris Calcaterra
    Chief Operating Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.